Wedbush Starts Surface Oncology (SURF) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SURF Hot Sheet
Price: $1.07 --0%
Rating Summary:
4 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 2
Rating Summary:
4 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 2
Join SI Premium – FREE
Wedbush analyst Robert Driscoll initiates coverage on Surface Oncology (NASDAQ: SURF) with a Outperform rating and a price target of $12.00.
For an analyst ratings summary and ratings history on Surface Oncology click here. For more ratings news on Surface Oncology click here.
Shares of Surface Oncology closed at $5.46 yesterday.
You May Also Be Interested In
- Citi initiates ATI Inc. coverage with Buy rating, $229 target
- CLSA Starts Busy Ming Group (1768:HK) at Outperform (2)
- Needham Starts Nlight (LASR) at Buy, 'LT Outlook Bright As Directed Energy Leadership Shines'
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
